|Category:||Emerging Biotech Company|
|Date:||April 25, 2023|
|Speaker:||Andrin Oswald, Incoming CEO|
Somagenetix is a spin-off of the University of Zurich.
Our platform technology allows for targeted and safe CURE of a wide range of genetic phagocyte disorders, such as macrophage-related immunodeficiencies, e.g., Chronic Granulomatous disease (CGD), or microglia-related neurological disorders, e.g., Fronto- Temporal-Dementia (FTD) and many others.